AU2638602A - Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings - Google Patents

Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Info

Publication number
AU2638602A
AU2638602A AU2638602A AU2638602A AU2638602A AU 2638602 A AU2638602 A AU 2638602A AU 2638602 A AU2638602 A AU 2638602A AU 2638602 A AU2638602 A AU 2638602A AU 2638602 A AU2638602 A AU 2638602A
Authority
AU
Australia
Prior art keywords
factor vii
coagulation factor
activated coagulation
thrombolytic therapy
bleedings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2638602A
Other languages
English (en)
Inventor
Cord Skamira
Jean Marie Stassen
Gerhard Heusel
Wolfgang Wienen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of AU2638602A publication Critical patent/AU2638602A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2638602A 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings Pending AU2638602A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128252A EP1216709A1 (en) 2000-12-21 2000-12-21 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings
PCT/EP2001/015132 WO2002049665A2 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Publications (1)

Publication Number Publication Date
AU2638602A true AU2638602A (en) 2002-07-01

Family

ID=8170769

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2638602A Pending AU2638602A (en) 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings
AU2002226386A Ceased AU2002226386B2 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002226386A Ceased AU2002226386B2 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings

Country Status (25)

Country Link
US (2) US20040087502A1 (xx)
EP (2) EP1216709A1 (xx)
JP (1) JP2004516273A (xx)
KR (1) KR20030063454A (xx)
CN (1) CN1482919A (xx)
AT (1) ATE353666T1 (xx)
AU (2) AU2638602A (xx)
BR (1) BR0116151A (xx)
CA (1) CA2431986A1 (xx)
CY (1) CY1106363T1 (xx)
CZ (1) CZ300670B6 (xx)
DE (1) DE60126650T2 (xx)
DK (1) DK1343523T3 (xx)
EC (1) ECSP034647A (xx)
ES (1) ES2280429T3 (xx)
HU (1) HUP0302574A3 (xx)
IL (1) IL155886A0 (xx)
MX (1) MXPA03005641A (xx)
NZ (1) NZ549850A (xx)
PL (1) PL205878B1 (xx)
PT (1) PT1343523E (xx)
RU (1) RU2286796C2 (xx)
SI (1) SI1343523T1 (xx)
WO (1) WO2002049665A2 (xx)
ZA (1) ZA200304140B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512316A (pt) * 2004-06-21 2008-02-26 Novo Nordisk Healthcare Ag métodos para prevenir ou atenuar uma ou mais complicações da hemorragia intracerebral e para prevenir ou atenuar uma ou mais complicações da ich em uma maioria de pacientes com ich, e, uso de um primeiro agente de coagulação
WO2007009895A2 (en) * 2005-07-15 2007-01-25 Novo Nordisk Health Care Ag USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY
JP2011509978A (ja) 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
RU2552339C1 (ru) * 2014-02-19 2015-06-10 Общество с ограниченной ответственностью фирма "Технология-Стандарт" Способ профилактики кровотечений, вызванных применением стрептокиназы, в эксперименте

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

Also Published As

Publication number Publication date
RU2003122362A (ru) 2005-02-10
WO2002049665A2 (en) 2002-06-27
EP1216709A1 (en) 2002-06-26
RU2286796C2 (ru) 2006-11-10
MXPA03005641A (es) 2004-12-03
CZ20031743A3 (cs) 2003-11-12
CZ300670B6 (cs) 2009-07-15
EP1343523B1 (en) 2007-02-14
CA2431986A1 (en) 2002-06-27
PT1343523E (pt) 2007-03-30
IL155886A0 (en) 2003-12-23
US20040087502A1 (en) 2004-05-06
PL205878B1 (pl) 2010-06-30
ATE353666T1 (de) 2007-03-15
SI1343523T1 (sl) 2007-04-30
BR0116151A (pt) 2003-10-21
DE60126650D1 (de) 2007-03-29
ES2280429T3 (es) 2007-09-16
KR20030063454A (ko) 2003-07-28
PL361855A1 (en) 2004-10-04
JP2004516273A (ja) 2004-06-03
NZ549850A (en) 2008-04-30
US20080286259A1 (en) 2008-11-20
EP1343523A2 (en) 2003-09-17
CN1482919A (zh) 2004-03-17
DK1343523T3 (da) 2007-04-10
ECSP034647A (es) 2003-07-25
ZA200304140B (en) 2004-04-22
HUP0302574A3 (en) 2010-01-28
HUP0302574A2 (hu) 2003-10-28
DE60126650T2 (de) 2007-10-31
CY1106363T1 (el) 2011-10-12
AU2002226386B2 (en) 2005-12-22
WO2002049665A3 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
PT1039887E (pt) Metodos para o tratamento de neuro e nefro disturbios e de toxicidades terapeuticas usando compostos de aminotiol
WO1997047296A3 (en) Compositions comprising vanadium compounds for use in the treatment of proliferative disorders and arthropathies
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
MXPA06003163A (es) Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
NO20021035L (no) Fremgangsmåter for anvendelse av rasktvirkende selective serotonin gjenopptakningsinhibitorer for behandling av seksuelldysfunksjon
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
AU2638602A (en) Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings
HRP20040383B1 (en) Non-neurotoxic plasminogen activating factors for treating stroke
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
CA2461117A1 (en) Botulinus toxin for treatment of body odour
MXPA03010743A (es) Uso de inhibidores de il-18 para el tratamiento o prevencion de lesiones del sistema nervioso central.
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
WO2004026252A3 (en) Glioma treatments
HK1054506A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії